1612: Regulation of Inflammation to Prevent Cataract Surgery Complications

Grant Status: Closed

Grant Amount: $37,410
Heather Chandler, PhD; Ohio State University
January 1, 2012 - June 30, 2013

Sponsor(s): Boston Terrier Club of America, Health & Rescue Foundation of the Petit Basset Griffon Vendeen Club of America

Breed(s): -All Dogs
Research Program Area: Ophthalmology
Donate to Support this Research Program Area

Project Summary

Cataracts are a progressive change to the lens of the eye, resulting in cloudiness and interference with vision. Cataracts are the most common cause of blindness in dogs. Surgery and placement of an intraocular lens implant (IOL) can restore normal vision. Although every effort is made to remove as much lens material as possible during cataract surgery, it is inevitable that some lens cells remain. These cells will migrate and proliferate, resulting in the most common complication to surgery, posterior capsule opacification (PCO). PCO interferes with light transmission and results in secondary vision loss. Cataracts occur in all breeds and PCO occurs in 100% of canine post-operative patients. Unfortunately, there is no consistently effective treatment for canine PCO. Studies performed by us and others, have found that use of a commonly prescribed drug, Cyclosporine A (CsA) can decrease PCO formation and decrease post-operative inflammation. We believe that CsA may provide a safe and reliable option to prevent PCO in dogs. In a laboratory setting, we have concluded that because standard IOLs can only delivery substantial doses of drug for 24 hours and 5 days of drug delivery is needed to prevent PCO formation, commercially available IOLs are not an ideal way to deliver CsA inside the eye. We are working on characterization of a new biocompatible, biodegradable, injectable, and inert composite to be placed within the lens capsule following surgery. We have shown this composite has a good solid-to-gel transition that allows the compound to be injected during cataract surgery but remain within the capsule for extended periods of time postoperatively. We have successfully synthesized the gel in the laboratory and will continue examining the properties of the gel and its drug delivery capabilities. The second goal of our study was to evaluate the potential toxicity of CsA to other tissues within the eye. Our studies have shown that CsA exposure does not cause overt damage to the vulnerable corneal endothelial cells. We are continuing to build evidence that extended release of CsA will be safe for use inside the eye. This study supports the use of controlled release of CsA following cataract surgery, giving veterinary ophthalmologists a new method of restoring excellent long-term vision in dogs that have been blinded by cataracts.


Chandler, H. L., Gervais, K. J., Lutz, E. A., Curto, E. M., Matusow, R. B., Wilkie, D. A., & Gemensky-Metzler, A. J. (2015). Cyclosporine A prevents ex vivo PCO formation through induction of autophagy-mediated cell death. Experimental Eye Research, 134, 63–72. https://doi.org/10.1016/j.exer.2015.03.020

Help Future Generations of Dogs

Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.

Learn How to Help

Get Canine Health News:
Please leave this field empty
American Kennel Club Canine Health Foundation, Inc

8051 Arco Corporate Dr.
Suite 300
Raleigh, NC 27617

Tax ID# 13-3813813


© 2021 AKC Canine Health Foundation | Privacy Policy | Site Map

Site by Blackbaud, Inc.